Finerenone shows promise for restoring fertility in premature ovarian insufficiency
In patients with premature ovarian insufficiency (POI), finerenone, a drug approved for slowing progressive kidney function decline associated with type 2 diabetes, can promote the development of follicles into mature oocytes yielding viable embryos, according to breakthrough findings by researchers from the University of Hong Kong (HKU).
